Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours.

ABSTRACT:

Background

Certain paediatric nervous system malignancies have dismal prognoses. Retinoic acid (RA) is used in neuroblastoma treatment, and preclinical data indicate potential benefit in selected paediatric brain tumour entities. However, limited single-agent efficacy necessitates combination treatment approaches.

Methods

We performed drug sensitivity profiling of 76 clinically relevant drugs in combination with RA in 16 models (including patient-derived tumouroids) of the most common paediatric nervous system tumours. Drug responses were assessed by viability assays, high-content imaging, and apoptosis assays and RA relevant pathways by RNAseq from treated models and patient samples obtained through the precision oncology programme INFORM (n = 2288). Immunoprecipitation det

SUBMITTER: Seiboldt T 

PROVIDER: S-EPMC11333474 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature